Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin

American Journal of Psychiatry

Volumn 163, Issue 8, 2006, Pages 1342-1347

  Matthews, Annette M ^a   Fireman, Marian ^b   Zucker, Betsy ^b   Sobel, Michelle ^b   Hauser, Peter ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE; METHADONE; OLANZAPINE; OPIATE; PEGINTERFERON; RIBAVIRIN; SERTRALINE; ANTIVIRUS AGENT; INTERFERON;

ADULT; ANOREXIA; CASE REPORT; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DISEASE EXACERBATION; FATIGUE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; IRRITABILITY; MALE; MANIA; PARANOID SCHIZOPHRENIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT INDICATION; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; ADDICTION; ARTICLE; COCAINE DEPENDENCE; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; OPIATE ADDICTION; PATIENT CARE PLANNING; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BEHAVIOR, ADDICTIVE; COCAINE-RELATED DISORDERS; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PATIENT CARE PLANNING; RECURRENCE; RIBAVIRIN; RISK ASSESSMENT; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 85047699803     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.8.1342     Document Type: Conference Paper

References (22)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562
2. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infections and HCV-related chronic disease. MMWR 1998; 47:1-39
3. Kim AI, Saab S: Treatment of Hepatitis C. Am J Med 2005; 118:808-815
4. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ: Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004; 161:429-435
5. Schafer M, Boetsch T, Laakmann G: Psychosis in a methadone substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000;95:1101-1104
6. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G: A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124
7. Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38-47
8. Management of Hepatitis C: 2002: Consensus Statements: NIH Consensus Development Program, vol 19, number 1. Bethesda, Md, NIH, 2002, pp 1-44
9. Schaefer M, Heinz A, Backmund M: Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004; 99:1167-1175
10. Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P: Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening and a component of a comanagement model of care. Clin Infect Dis 2005; 40(suppl 5):S286-S291
11. Fireman M: Hepatitis C treatment and substance abuse disorders. Psychiatr Ann 2003; 33:402-408
12. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-193
13. Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S: Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 2005; 77:214-224
14. Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2004; 67:117-123
15. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7:942-947
16. Edlin BR: Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36(suppl 1):S210-S219
17. Dalgard O, Bjoro K, Helium K, Myrvang B, Skaug K, Gutigard B, Bell H: Treatment of chronic HCV in injection drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-49
18. Backmund M, Meyer K, Edlin BR: Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-1553
19. Van Thiel DH, Anantharaju A, Creech S: Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98:2281-2288
20. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, Bordonaro F, Pulvirenti D, Italiano C, Caruso L: Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24:1627-1635
21. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J: Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23:119-127
22. Renton KW: Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92:147-163